PMID: 16622542Apr 20, 2006Paper

The National Health Surveillance Agency, ANVISA, and clinical research in Brazil

Revista da Associação Médica Brasileira
Sérgio de Andrade Nishioka, Paula Frassineti Guimarães de Sá

Abstract

Conduction of clinical trials with drugs in Brazil requires prior approval by Committees for Ethics in Research (CEPs) and, in certain cases, by the National Commission for Ethics in Research (CONEP). Approval by the National Health Surveillance Agency (ANVISA), through its Office for New Drugs, Research and Clinical Trials (GEPEC), is currently required only for drugs and medical devices manufactured in other countries and therefore need permission to be imported. This article briefly reviews the history of clinical research regulation in Brazil, then presents an overview of the current regulatory role of ANVISA and its future prospective. Major points discussed are the new forthcoming ANVISA regulations, with emphasis on adverse event notifications and inspections/audits on clinical trials and their impact on clinical research in Brazil, from the standpoint of the industry, university, contract research organizations, physicians and other health professionals. It should be stressed that to decide upon the licensing of new drugs ANVISA must obtain information from clinical trials.

Citations

Oct 10, 2007·Acta Cirúrgica Brasileira·Elaine Maria de Oliveira Alves, Paulo Tubino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Related Papers

Pediatrics
Jeffrey R BotkinBioethics and Legal Work Group of the Newborn Screening Translational Research Network
Deutsche medizinische Wochenschrift
V PlateH Schweim
Bioethics
Debora DinizVolnei Garrafa
Journal of Medical Ethics
Benjamin HerrerosMiguel A Sánchez-González
© 2022 Meta ULC. All rights reserved